スギ花粉症に対するトラニラストの効果 神奈川県多施設による３年間の検討

Abstract

We studied the preventive and therapeutic effects of Tranilast in patients with Japanese cedar pollinosis from 1986 to 1988.Patients with only mild nasal symptoms or none at all who were hospitalized before the Japanese cedar pollen season served as the preventive group, and those with symptoms who were hospitalized after pollen dissemination were the therapeutic group. Tranilast, 3 capsules a day, was administered orally for more than 4 weeks.The severity and condition of the nasal symptoms, after the preventive or therapeutic use of this drug were observed, and the need for additional drugs.The starting date, pattern and total Japanese cedar pollen count during the 3 seasons differed.In the Tranilast preventive group the rates of “effectiveness” were 50.0%, 80.8% and 72.4% in the seasons. In the Tranilast therapeutic group the “effectiveness” rates were 66.7%, 45.5% and 62.3%. Side effects were observed in 1.76% during the 3 seasons, but none were serious.Symptoms were more significantly inhibited in the preventive group than in the therapeutic group, and the use of concomitant drugs was less. Tranilast was also useful in the therapeutic group.Tranilast is considered to be an excellent basic drug for Japanese cedar pollinosis because concomitant drugs can be easily selected since there is no anti-histamine action or drowsiness.